Novo Nordisk Raises Its 2026 Guidance for the Third Time: the Wegovy Pill Drives Sales and Shares Rebound After a Year of Free Fall

On Wednesday, November 4, 2026, Novo Nordisk reported third-quarter results with sales and adjusted operating profit clearly above analyst consensus, and raised its full-year 2026 guidance for sales and adjusted profit for the third time this year. Shares, which trade on both the Copenhagen exchange and the New York Stock Exchange (NYSE: NVO), rose as much as 6.6% at the open of the Danish market, though the gain moderated during the session.

Context: from February's guidance crisis to the third consecutive upgrade

To understand why this result matters, you have to go back to February 3, 2026. That day, Novo Nordisk badly surprised the market by guiding to a 5%-13% decline in adjusted sales and operating profit for all of 2026 — far below what consensus expected — citing lower US prices for Wegovy, fierce competition from Eli Lilly, and the expiration of semaglutide patents in several non-US markets. The market's reaction was severe: different sources put the one-day drop in the stock that day in Copenhagen at between 15% and 20%, one of the steepest single-session declines in the company's recent history.

That blow landed in an already turbulent year for Novo Nordisk's governance: then-CEO Lars Fruergaard Jørgensen had announced his early departure back in May 2025 after the stock's collapse and Eli Lilly's advances in the obesity market, and was replaced on August 7, 2025 by Maziar Mike Doustdar, previously the company's head of international operations. The November 4, 2026 result is therefore the third full quarterly report under Doustdar's leadership, and it confirms a gradual recovery path: after guiding to -5%/-13% in February, the company raised the range to -4%/-12% on May 6 (with the year's first quarterly report, supported by the strong reception of the Wegovy pill), raised it again to 0%/-6% on August 4, and now, on November 4, sets it at -2%/+2% — meaning the company no longer rules out ending the year with positive adjusted sales growth, something unthinkable nine months ago.

As the chart shows, the guidance range has not only shifted upward each quarter but has also narrowed: from an 8-percentage-point spread in February to just 4 points now, a sign that visibility into the business has improved substantially as the year progressed.

The concrete, verified data: sales and profit above consensus, with caveats

The third-quarter figures, disclosed in the Form 6-K filed with the SEC, are as follows:

• Adjusted sales: DKK 79.2 billion, versus an analyst consensus (Bloomberg, per Placera) of approximately DKK 73.4 billion — a beat of roughly 8%.
• Adjusted operating profit: DKK 31.72 billion, up 27% year-on-year at constant exchange rates, against a consensus estimate of between DKK 28.4 billion and DKK 28.7 billion depending on the source — a beat of approximately 12%.
• Reported (non-adjusted) profit, lower than the adjusted figure suggests: the GAAP result was weighed down by a DKK 8.7 billion impairment charge, a one-off, non-cash item that does not affect the adjusted guidance the market tracks.
• Obesity Care (the obesity division): DKK 26.15 billion, +22% year-on-year at constant exchange rates, with combined Wegovy pill and injectable sales growing 21% together, also at constant exchange rates.
• Within that division, two opposite stories: US injectable Wegovy sales fell 13% at constant exchange rates — the direct reflection of the pricing pressure that triggered February's profit warning — while sales of the oral semaglutide pill, launched in January 2026, reached DKK 4.178 billion in the quarter, up from DKK 3.141 billion in the second quarter and DKK 2.26 billion in the first.
• Guidance raised: adjusted sales and operating profit now expected between -2% and +2% (previously -6%/0%), and free cash flow now guided at DKK 60-70 billion (previously DKK 45-55 billion).

As the chart shows, the Wegovy pill has nearly doubled its quarterly sales in just two quarters (from DKK 2.26 billion to DKK 4.178 billion between the first and third quarters), becoming the main driver behind the year's three guidance upgrades — at least partially offsetting the deterioration of the US injectable business.

As for the stock's reaction: after rising as much as 6.6% at the open in Copenhagen, the gain narrowed to roughly 1.9% by mid-morning (10:23 GMT), before regaining strength later in the session — several analysts, including Indmoney, put the close at a gain of around 5%. That intraday volatility is consistent with a stock that, before this report, had accumulated a very severe deterioration over the preceding twelve months since February's profit warning.

Sector/asset analysis: why this report matters beyond Novo Nordisk

Large-cap healthcare and biotech. Novo Nordisk is one of Europe's largest pharmaceutical companies by market capitalization and a key component of global healthcare indices; a third consecutive guidance upgrade reduces the idiosyncratic risk that had weighed on the European healthcare sector for much of 2026, and it's a signal that sector fund managers (healthcare, defensive consumer staples) will watch closely to gauge whether Novo Nordisk's "rough patch" is behind it.

The GLP-1 duopoly and Eli Lilly. Eli Lilly, with its tirzepatide-based Zepbound and Mounjaro, has been the main beneficiary of Novo Nordisk's struggles, reaching a $1 trillion market capitalization in November 2025 and a US obesity-and-diabetes market share above 60%, versus just over 39% for Novo Nordisk at the end of 2025. That Novo Nordisk is regaining traction with its oral pill — a more convenient format than the weekly injection, and one in which Novo got to the US market first — matters for any investor positioned in the GLP-1 trade: this is no longer a single-winner story, but genuine competition on two fronts (injectable and oral) where each company is defending different ground.

Currency and companies with revenue in Danish krone/euros. Much of Novo Nordisk's business is billed in dollars but reported in Danish krone (pegged to the euro via the ERM II fixed exchange-rate mechanism); investors in the New York-listed ADR (NVO) need to keep watching the gap between the "constant exchange rate" growth the company highlights in its releases and growth reported in dollars, which can diverge substantially if the dollar moves sharply against the krone in coming quarters.

Fixed income and defensive growth versus value. Novo Nordisk is traditionally a "growth" stock but with a defensive profile (demand with low economic-cycle sensitivity); its recovery in an environment of still-elevated rates (as this blog has covered in recent weeks regarding the 10-year Treasury and the Fed) reinforces the relative appeal of quality pharmaceuticals with predictable cash generation versus sectors more dependent on cheap financing — though this quarter's DKK 8.7 billion impairment charge is a reminder that even these companies aren't immune to painful accounting adjustments after a year of resetting expectations.

What to watch next

• FDA decision on CagriSema for weight management, expected in the fourth quarter of 2026: the application was submitted to the agency in December 2025, backed by the REDEFINE 1 and REDEFINE 2 trials, and an approval — with a launch targeted for early 2027 — would be the most immediate catalyst for the stock following this report.
• US injectable Wegovy sales trend: the 13% constant-currency decline in the third quarter is the weakest part of the report; the market will want to see whether it stabilizes in Q4 as the pricing structure agreed with the Trump administration settles in (a November 2025 deal that set reference prices of $149 for starter doses of the oral pills and around $245-$350 for the injectable versions).
• The 2026 full-year results and initial 2027 guidance, expected around February 3, 2027 — a symbolic date, exactly one year after the profit warning that triggered the crisis: this will be the first real test of whether this quarter's recovery holds or whether 2027 brings a new negative surprise.
• Upcoming CagriSema clinical trial data, including the higher-dose Phase 3 trial planned for the second half of 2026 and the REDEFINE 11 trial, whose data is expected in the first half of 2027 and which will measure the drug's maximum weight-loss potential.
• Eli Lilly's results (expected around early February 2027) as a direct contrast: a slowdown in Zepbound in the fourth quarter would reinforce Novo Nordisk's recovery narrative; an acceleration would confirm that competition keeps intensifying.

Historical parallel: the last time a pharma company this size crashed and recovered in the same year

The pattern of "a severe profit warning followed by successive guidance upgrades in subsequent quarters" is not unprecedented in the pharmaceutical sector, but it's unusual for it to happen at a company the size of Novo Nordisk — among the world's largest pharmaceutical companies by market cap before February's crisis — within such a short span: barely nine months separate February's -5%/-13% guidance from November's -2%/+2% guidance. CEO Mike Doustdar himself warned in February that the situation "would get worse before it gets better," a statement that in hindsight has proven to be a reasonably accurate description of the nine months that followed: a first quarter of stabilization supported by a one-off reversal of US 340B program provisions, a second quarter of real 7% constant-currency growth, and this third quarter with a Wegovy pill that now generates more than DKK 4 billion in quarterly sales, up from DKK 2.26 billion in the year's first quarter.

The lesson for an investor is twofold: first, that a profit warning of this magnitude at a company with a product still in structural expansion (global demand for GLP-1 drugs keeps growing, even as Novo Nordisk loses relative share to Lilly) can be a market overreaction that corrects in subsequent quarters if management executes well; and second, that the speed of that correction — three guidance upgrades in nine months — is itself an unusually fast signal that either the previous outlook had been excessively pessimistic, or that the new management team managed to stabilize the business faster than the market itself expected back in February.